Spin?l m?rphine f?r p?st?per?tive ?n?lgesi? - safety and effectiveness depending on doses

S?fety ?nd effe?tiveness ?f different spin?l m?rphine d?ses f?r p?st?per?tive ?n?lgesi? ?fter prim?ry hip repl??ement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN37212222

Enrollment

Registered

2022-04-20

Start date

2020-06-01

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outcomes after different spinal morphine doses for patients undergoing hip replacement surgery Surgery

Interventions

Using https://www.r?nd?mizer.?rg/ p?tients are divided int? three study gr?ups. Before surgery: Gr?up I receive spinal anaesthesia with S?l. Bupiv???ine 15-18 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient is scheduled for total hip replacement under spinal anaesthesia 2. Aged 18-80 years 3. Body mass index (BMI) <35 kg/m² 4. ASA Physical Status Classification System < IV

Exclusion criteria

Exclusion criteria: 1. Patient rejection 2. Drug allergy to medications included in this study 3. Severe respiratory disorders 4. BMI >35 kg/m² 5. Patient is not able to understand the main points of the research 6. Patient is enrolled in another clinical trial

Design outcomes

Primary

Measure	Time frame
1. Pain measured using the numeric rate scale (NRS) at baseline, 4, 7, 12, ?nd 24 hours 2. Respiratory rate (x/min) measured using a vital sign monitor in the postoperative recovery room at baseline, 4, 7, 12, ?nd 24 hours 3. Arterial blood oxygen saturation (Sp?2,%) measured using a vital sign monitor in the postoperative recovery room at baseline, 4, 7, 12, ?nd 24 hours	—

Secondary

Measure	Time frame
1. M?rphine 10 mg s/? is injected by a nurse on patient request if pain is more than 5 points (by NRS), each injected dose is noted by a nurse in the narcotic drug copy-book and ??nsumpti?n is counted in 24 h by the researcher and noted in the research protocol 2. Additional oxygen consumption: time (min) and speed (l/min) of additional oxygen supply. The period of time when the patient has inhaled additional oxygen and the speed (l/min) of the supply is noted in the patient observation form by a nurse and in the research protocol by the researcher. 3. The incidence of any adverse reactions (n?use?, v?miting, it?hing, urine retention) measured using a formula (incidence = cases/total number of patients in the research group). The case of each adverse reaction is noted by a nurse in the patient observation form during 48 h after surgery.	—

Measure

Time frame

1. M?rphine 10 mg s/? is injected by a nurse on patient request if pain is more than 5 points (by NRS), each injected dose is noted by a nurse in the narcotic drug copy-book and ??nsumpti?n is counted in 24 h by the researcher and noted in the research protocol 2. Additional oxygen consumption: time (min) and speed (l/min) of additional oxygen supply. The period of time when the patient has inhaled additional oxygen and the speed (l/min) of the supply is noted in the patient observation form by a nurse and in the research protocol by the researcher. 3. The incidence of any adverse reactions (n?use?, v?miting, it?hing, urine retention) measured using a formula (incidence = cases/total number of patients in the research group). The case of each adverse reaction is noted by a nurse in the patient observation form during 48 h after surgery.

—

Countries

Latvia

Contacts

Public ContactEva Vitola

eva.vitola@stradini.lv+371 (0)20307834

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 10, 2026